Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5895MR)

This product GTTS-WQ5895MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5895MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3704MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ6020MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ5979MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ3605MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ3953MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ10482MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ15489MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ2907MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG827
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW